Christian Angermayer, founder of talks longevity investment, optimism on SPAC deal and light at the end of the tunnel for the biotech market.
One of the speakers at October’s Rejuvenation Startup Summit in Berlin is the entrepreneur and investor, Christian Angermayer.
With more than $3 billion under management through his Apeiron Investment Group, Angermayer is a major figure in the longevity sector through his platform biotech companies Cambrian and Rejuveron – building on his belief that everyone wants to live healthier, happier and longer lives.
Ahead of Berlin’s meeting, our editor-in-chief caught up with Angermayer for a video interview in which he shares his views on subjects ranging from longevity investing, the biotech market, and what’s happening with his $200 million SPAC with David Sinclair and Peter Attia.
Visit Longevity. Technology — https://bit.ly/3PwtH8Y
Follow Longevity. Technology on:
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf
Comments are closed.